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Abstract. 
 
The dystrophin–glycoprotein complex (DGC) 
is a multisubunit complex that spans the muscle plasma 
membrane and forms a link between the F-actin cyto-
skeleton and the extracellular matrix. The proteins of 
the DGC are structurally organized into distinct sub-
complexes, and genetic mutations in many individual 
components are manifested as muscular dystrophy. We 
recently identiﬁed a unique tetraspan-like dystrophin-
associated protein, which we have named sarcospan 
(SPN) for its multiple sarcolemma spanning domains 
(Crosbie, R.H., J. Heighway, D.P. Venzke, J.C. Lee, and 
K.P. Campbell. 1997. 
 
J
 
.
 
 Biol
 
.
 
 Chem
 
. 272:31221–31224). 
To probe molecular associations of SPN within the 
DGC, we investigated SPN expression in normal mus-
cle as a baseline for comparison to SPN’s expression in 
animal models of muscular dystrophy. We show that, in 
addition to its sarcolemma localization, SPN is enriched 
at the myotendinous junction (MTJ) and neuromuscu-
lar junction (NMJ), where it is a component of both the 
dystrophin– and utrophin–glycoprotein complexes. We 
demonstrate that SPN is preferentially associated with 
the sarcoglycan (SG) subcomplex, and this interaction 
is critical for stable localization of SPN to the sarco-
lemma, NMJ, and MTJ. Our experiments indicate that 
assembly of the SG subcomplex is a prerequisite for 
targeting SPN to the sarcolemma. In addition, the SG–
SPN subcomplex functions to stabilize 
 
a
 
-dystroglycan 
to the muscle plasma membrane. Taken together, our 
data provide important information about assembly 
and function of the SG–SPN subcomplex.
Key words: sarcospan • dystrophin • sarcoglycans • 
tetraspans • muscular dystrophy
 
T
 
HE
 
 dystrophin–glycoprotein complex (DGC
 
1
 
; Camp-
bell and Kahl, 1989; Ervasti et al., 1990, 1991;
Yoshida and Ozawa, 1990; Ervasti and Campbell,
1991) is comprised of peripheral and integral membrane
proteins and provides a structural linkage between the ex-
tracellular matrix and the intracellular cytoskeleton of
muscle cells. Several forms of muscular dystrophy arise
from primary mutations in genes encoding dystrophin-
associated proteins (for review see Campbell, 1995; Straub
and Campbell, 1997). Patients with mutations in the dys-
trophin gene develop either Duchenne or Becker muscu-
lar dystrophy, which is characterized by progressive wast-
ing of skeletal muscles. Likewise, a nonsense mutation in
the murine dystrophin gene (
 
mdx
 
) eliminates expression
of dystrophin and, consequently, the DGC proteins are re-
duced at the sarcolemma. While the function of the DGC
is obviously essential for normal muscle physiology, its
precise role in muscle function is unclear. It has been hy-
pothesized that this transmembrane protein complex pro-
vides mechanical support to the plasma membrane during
myofiber contraction (Weller et al., 1990; Petrof et al.,
1993). More recently, data from several laboratories have
suggested that the DGC may also play a role in cellular
communication, as highlighted by the association of this
complex with known signaling molecules (Brenman et al.,
1995; Yang et al., 1995; Chang et al., 1996).
The proteins that comprise the DGC are structurally or-
ganized into three distinct subcomplexes. These are the cy-
toskeletal proteins, dystrophin and syntrophins; the dys-
troglycans (DGs; 
 
a 
 
and 
 
b 
 
subunits); and the sarcoglycans
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1. 
 
Abbreviations used in this paper:
 
 DG, dystroglycan; DGC, dystrophin–
glycoprotein complex; EOM, extraocular muscle; LGMD, limb-girdle
muscular dystrophy; 
 
mdx
 
, murine dystrophin gene; MTJ, myotendinous
junction; NMJ, neuromuscular junction; SG, sarcoglycan; Sgca-null, 
 
a
 
-SG
deficient mice; SPN, sarcospan; utrn
 
2
 
/
 
2
 
, utrophin deficient; 
 
mdx
 
:utrn
 
2
 
/
 
2
 
,
utrophin–dystrophin deficient; wt, wild-type. 
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(SGs; 
 
a
 
, 
 
b
 
, 
 
g
 
, and 
 
d 
 
subunits). Exactly how these proteins
are arranged with respect to one another is uncertain, but
interactions between subcomplexes are clearly important
for targeting to the sarcolemma, as well as for membrane
stabilization. Recent reports have demonstrated that the
NH
 
2
 
 terminus of dystrophin interacts directly with F-actin
in an extended, lateral fashion, similar to many actin side-
binding proteins (Rybakova et al., 1996; Rybakova and
Ervasti, 1997; Amann et al., 1998). Dystrophin connects
with the other DGC subcomplexes through its COOH-ter-
minal domain, which binds directly to the COOH terminus
of 
 
b
 
-DG, an integral membrane protein with a single
transmembrane helix (Jung et al., 1995). 
 
b
 
-DG, in turn,
binds 
 
a
 
-DG, anchoring it to the extracellular surface of the
sarcolemma. 
 
a
 
-DG serves as a receptor for laminin 2,
thereby completing the physical connection between the
actin cytoskeleton and the extracellular matrix (Ervasti
and Campbell, 1993).
The SG subcomplex is composed of four distinct single-
pass transmembrane glycoproteins, referred to as 
 
a
 
-, 
 
b
 
-, 
 
g
 
-,
and 
 
d
 
-SG (for review see Lim and Campbell, 1998). The
SGs, in conjunction with 
 
b
 
-DG, mediate attachment of
 
a
 
-DG to the muscle plasma membrane. A defect in any
one of the SGs results in specific loss of the SG subcom-
plex, destabilization of 
 
a
 
-DG, and sarcolemma damage
(Holt et al., 1998). Autosomal recessive limb-girdle mus-
cular dystrophy (LGMD) types 2D, 2E, 2C, and 2F are
caused by mutations in 
 
a
 
-, 
 
b
 
-, 
 
g
 
-, and 
 
d
 
-SG, respectively
(Roberds et al., 1994; Bönnemann et al., 1995; Lim et al.,
1995; Noguchi et al., 1995; Piccolo et al., 1995; Jung et al.,
1996; Nigro et al., 1996a,b; Passos-Bueno et al., 1996).
Likewise, the BIO 14.6 hamster (Iwata et al., 1993; Ro-
berds et al., 1993), which serves as an animal model for
LGMD2F, has a large deletion in the 
 
d
 
-SG gene (Nigro et
al., 1997). BIO 14.6 hamsters display both cardiomyo-
pathic and myopathic features. Successful intervention of
disease progression has been achieved by introduction of a
recombinant 
 
d
 
-SG adenovirus into skeletal muscle of the
BIO 14.6 hamster (Holt et al., 1998). Targeted deletions of
the 
 
a
 
- (Duclos et al., 1998b) and 
 
g
 
-SG (Hack et al., 1998)
genes in mice result in dystrophic muscle phenotypes and
have provided additional animal models for LGMD.
We have recently characterized a novel 25-kD dystro-
phin-associated protein and have shown that it is an inte-
gral member of the DGC (Crosbie et al., 1997, 1998). We
have named this protein sarcospan (SPN) for its multiple
sarcolemma spanning helices, which are predicted based
on hydropathy analysis (Crosbie et al., 1997). Dendrogram
analysis shows that SPN is a member of the transmem-
brane four or tetraspan superfamily of proteins (Crosbie
et al., 1997). Each possess four transmembrane domains, a
large extracellular loop, and are thought to play important
roles in mediating transmembrane protein interactions
(Wright and Tomlinson, 1994; Maecker et al., 1997). These
characteristics make SPN unique among other dystrophin-
associated proteins. Furthermore, given the propriety of
tetraspan proteins for mediating protein–protein interac-
tions, SPN is structurally poised to be an important player
in facilitating interactions between subcomplexes of the
DGC. In the present study, we examine SPN expression in
several animal models of muscular dystrophy as a means
of assessing the molecular associations of SPN with sub-
complexes of the DGC. We find that SPN interacts with
the SGs, forming an SG–SPN protein complex.
 
Materials and Methods
 
cDNA Isolation and Sequencing
 
SPN cDNA clones were isolated by hybridization screening of a CLON-
TECH rabbit skeletal muscle cDNA library with a PCR-derived SPN
cDNA probe encoding exons 1–3. Sequence analysis of the clones was
performed using dye terminator cycling and analyzed on a 373 stretch flu-
orescent automated sequencer (PE Applied Biosystems). The nucleotide
and deduced amino acid sequences of rabbit SPN have been deposited in
the GenBank/EMBL/DDBJ data bank with the accession number
AF120276. Multiple sequence alignment was performed using the DNAsis
sequence analysis software (Hitachi Software Engineering, Inc.). Also, we
have isolated SPN cDNA clones independently from a mouse skeletal
muscle library and found clones identical to those found by Scott et al.
(1994).
 
Northern Blotting
 
Adult mouse multiple tissue Northern blots (CLONTECH Laboratories,
Inc.) containing 2 
 
m
 
g of poly (A)
 
1
 
 RNA per lane were probed with an ex-
pressed sequence tag corresponding to the 3
 
9
 
 untranslated region of
mouse SPN (GenBank accession number W83284). Identical results were
obtained when blots were hybridized with PCR-amplified probes repre-
senting the entire coding region (GenBank accession number U02487) of
mouse SPN.
 
Animal Models
 
Wild-type (wt; C57BL/10) and 
 
mdx
 
 (C57BL/10ScSn) mice, obtained from
Jackson ImmunoResearch Laboratories, Inc. were maintained at the Uni-
versity of Iowa Animal Care Unit in accordance with animal usage guide-
lines. The dystrophin transgenic mice have been described previously
(Cox et al., 1994; Rafael et al., 1994, 1996; Phelps et al., 1995). Male F1B
and BIO 14.6 cardiomyopathic hamsters were obtained from BioBreed-
ers. We have previously reported the generation and initial characteriza-
tion of the 
 
a
 
-SG deficient (Sgca-null) mice (Duclos et al., 1998b). The tar-
geted disruption of the 
 
a
 
-SG gene was accomplished by replacement of
exons 2 and 3, and flanking intronic sequences with the neomycin resis-
tance gene through homologous recombination (Duclos et al., 1998b).
Utrophin deficient (utrn
 
2
 
/
 
2
 
)
 
 
 
and utrophin–dystrophin deficient mice
(
 
mdx
 
:utrn
 
2
 
/
 
2
 
) have been described previously (Grady et al., 1997a,b).
Utrn
 
2
 
/
 
2
 
 and 
 
mdx
 
:utrn
 
2
 
/
 
2
 
 mice were maintained at Washington University
(St. Louis, MO).
 
Antibodies
 
mAbs against 
 
a
 
- (20A6), 
 
b
 
- (5B1), and 
 
g
 
-SG (21B5), as well as mAbs
against 
 
b
 
-DG (8D5) were generated in collaboration with Dr. Louise V.B.
Anderson (Newcastle General Hospital, Newcastle upon Tyne, UK).
mAb against 
 
a
 
-DG (IIH6) have been described by Ervasti and Campbell
(1991). Antibodies against the laminin 
 
a
 
2 chain (Allamand et al., 1997)
and the NH
 
2
 
 terminus of rabbit SPN (Rabbit 216; Crosbie et al., 1997)
have been described previously. For generating antibodies against mouse
SPN, two New Zealand White rabbits (rabbits 235 and 236; Knapp Creek
Farms) were injected at intramuscular and subcutaneous sites with a
COOH-terminal SPN–glutathione S transferase fusion protein (amino ac-
ids 186–216 of mouse SPN; CFVMWKHRYQVFYVGVGLRSLMAS-
DGQLPKA). Affinity purification of SPN antibodies was accomplished
using Immobilon-P (Millipore Corp.) strips containing the COOH-termi-
nal SPN–maltose-binding fusion protein. Antibody specificity was verified
for both immunofluorescence and immunoblotting by competition experi-
ments using the COOH-terminal SPN fusion protein and peptides synthe-
sized to the COOH-terminal region of mouse SPN (data not shown).
 
Immunofluorescence
 
Transverse muscle cryosections (7 
 
m
 
m) were analyzed by immunofluores-
cence as described in Crosbie et al. (1997). For extraocular muscle (EOM)
studies, rectus muscles (global layer) were examined. Affinity purified
rabbit 235 SPN antibody was incubated at a dilution of 1:50 and 1:10 with 
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mouse and hamster sections, respectively. After washing with TBS (10 mM
Tris-HCl, 150 mM NaCl, pH 7.4), the sections were incubated with Cy3-
conjugated secondary antibodies at a dilution of 1:250 (Jackson Immu-
noResearch Laboratories, Inc.) for 1 h at room temperature. For staining
of neuromuscular junctions (NMJs), samples were simultaneously incu-
bated with fluorescein-conjugated 
 
a
 
-bungarotoxin (1:1,000; Molecular
Probes, Inc.). After washing with TBS, the slides were mounted with
Vectashield mounting medium (Vector Labs Inc.) and observed under a
BioRad MRC-600 laser scanning confocal microscope. Digitized images
were captured under identical conditions.
 
Recombinant Adenovirus Injections
 
The human 
 
d
 
-SG cDNA sequence was subcloned into the pAdRSVpA ad-
enovirus vector through standard methods of homologous recombination
with Ad5 backbone dl309 by the University of Iowa Gene Transfer Vector
Core. Preparation of the recombinant adenovirus and the intramuscular
injections were performed as previously described (Holt et al., 1998). In
brief, 10
 
9
 
 viral particles in 100 
 
m
 
l of normal saline were injected into the
quadriceps femoris of 3-wk-old BIO 14.6 hamsters after the animals were
anesthetized by intraperitoneal injection of sodium pentobartital (Nem-
butal; Abbott Laboratories) at a calculated dose of 75 mg/kg. Quadriceps
muscle was collected 2 wk after the injection.
 
Preparation of Skeletal Muscle Membranes
 
KCl washed membranes from wt, 
 
mdx
 
, and Sgca-null mice were prepared
from skeletal muscle as described previously (Duclos et al., 1998b).
 
Isolation of the SG–SPN Subcomplex by
pH 11 Treatment
 
Purified DGC (Campbell and Kahl, 1989; Ervasti et al., 1990, 1991) from
rabbit skeletal muscle membranes was titrated to pH 11 using 1 M NaOH
and incubated for 1 h at room temperature with gentle mixing (Ervasti et al.,
1991) in a buffer consisting of 50 mM Tris, 0.1% digitonin, 175 mM NaCl,
0.1 mM PMSF, 0.75 mM benzamidine. The alkaline treated DGC was con-
centrated fourfold using Centricon-10 filters (Amicon Corp.). The sam-
ples were loaded onto 5–30% linear sucrose gradients in a buffer of 50 mM
Tris-HCL, 500 mM NaCl, 0.1% digitonin, 0.1 mM PMSF, 0.75 mM ben-
zamidine, pH 11. The gradients were centrifuged at 4
 
8
 
C in a Beckman Vti
65.1 vertical rotor for 2.5 h at 200,000 
 
g
 
. 16 0.8-ml fractions were collected
from the top of the gradient using an Isco model 640 density gradient frac-
tionator. The protein samples (60 
 
m
 
l) were separated by 3–15% SDS-
PAGE and immunoblotted, as described (vide infra).
 
Sucrose Gradient Separation of WGA Enriched 
Proteins from mdx Muscle
 
Quadriceps femoris muscle was dissected from 
 
mdx
 
 mice and snap frozen
in liquid nitrogen. Frozen tissue (1 g) was pulverized into small pieces with
a pestal and mortar filled with liquid nitrogen. The tissue was solubilized
by dounce homogenization in 10 ml of cold buffer A (50 mM Tris-HCl,
pH 7.8, 500 mM NaCl, 1.0% digitonin) with a cocktail of protease inhibi-
tors (0.6 
 
m
 
g/ml pepstatin A, 0.5 
 
m
 
g/ml aprotinin, 0.5 
 
m
 
g/ml leupeptin, 0.1
mM PMSF, 0.75 mM benzamidine, 5 
 
m
 
m calpain I inhibitor, and 5 
 
m
 
M
calpeptin). The samples were spun at 142,400 
 
g
 
 for 37 min at 4
 
8
 
C. The pel-
lets were resolublized with 5 ml of buffer A, rotated at 4
 
8
 
C for 1 h, and
centrifuged as before. The two supernatants were combined and incu-
bated overnight at 4
 
8
 
C with 1 ml of WGA–Sepharose (Vector Labs, Inc.).
The WGA–Sepharose was washed extensively (50 mM Tris-HCl, pH 7.8,
0.1% digitonin, 500 mM NaCl) and proteins were eluted with 0.3 M
N-acetyl glucosamine (Sigma Chemical Co.). Samples were concentrated
to 500 
 
m
 
l using a Centricon-30 filter and applied to a 5–30% sucrose gradi-
ent at pH 7.8, as described previously (Ervasti et al., 1991).
 
Immunoblotting
 
Protein samples were resolved under reducing conditions by 3–15% SDS-
PAGE and transferred to PVDF (Immobilon-P) membranes (Millipore
Corp.). PVDF membranes were probed with anti-SG mAbs, as described
previously (Holt et al., 1998). For mouse SPN immunoblotting, the mem-
branes were probed with affinity purified rabbit 235 antibody at a dilution
of 1:50. Note that for mouse SPN immunoblotting, proteins were resolved
on 3–15% SDS-PAGE under nonreducing conditions and transferred to
PVDF (Immobilon-P). For rabbit SPN staining, nitrocellulose blots were
probed with affinity purified rabbit 216 antibody as described (Crosbie et
al., 1997). For 
 
a
 
- and 
 
b
 
-DG staining, SDS-polyacrylamide gels were trans-
ferred to nitrocellulose (Immobilon-NC) and probed with IIH6 (1:3 dilu-
tion) and 20A6 (1:100 dilution). Following incubation with primary an-
tibodies, blots were probed with the appropriate HRP-conjugated
secondary antibodies (1:5,000; Boehringer Mannheim Corp.) and devel-
oped using enhanced chemiluminescence (SuperSignal; Pierce Chemi-
cal Co.).
 
In Vivo Reconstitution Experiments
 
A human SPN expression construct was prepared by PCR amplification of
cDNA using primers containing appropriate restriction sites for subclon-
ing into pcDNA3 (Pharmacia Biotech, Inc.). The SPN construct was engi-
neered to encode a myc-tag at the COOH terminus. All constructs were
verified by direct DNA sequence analysis performed by the DNA Core
Facility at the University of Iowa (Iowa City, IA). Full-length myc-tagged
 
a
 
-, 
 
b
 
-, 
 
g
 
-, and 
 
d
 
-SG pcDNA3 (Pharmacia Biotech Inc.) expression con-
structs have been previously described (Holt and Campbell, 1998). Con-
struction and design of the Grb2 cDNA expression vector has been de-
scribed (Holt et al., 1996). CHO cells were electroporated with SG and
SPN expression constructs (
 
z
 
5 
 
m
 
g of each plasmid DNA) at 340 V at 950
 
m
 
F using a BioRad electroporator, as previously described (Holt and
Campbell, 1998). 30 h after transfection, cells were analyzed for protein
expression by SDS-PAGE and immunoblotting. Membrane surface pro-
teins were biotinylated using membrane impermeant sulfo-NHS-biotin
(Pierce Chemical Co.) as described previously for the SGs expressed in
CHO cells (Holt and Campbell, 1998). Immunoprecipitation using a 
 
b
 
-SG
mAb (5B1) and analysis of protein samples by SDS-PAGE and immuno-
blotting with an anti-myc mAb (9E10) were performed as documented in
Holt and Campbell (1998).
 
Results
 
SPN is the most recently identified dystrophin-associated
protein, and therefore the least characterized. Hydropathy
analysis of the primary amino acid sequences of human
(Heighway et al., 1996; Crosbie et al., 1997) and murine
(Scott et al., 1994) SPN predicts a protein with intracellu-
lar NH
 
2
 
 and COOH termini, and four transmembrane do-
mains. We report determination of the primary structure
of rabbit SPN, as deduced from a rabbit skeletal muscle
cDNA (Fig. 1 a). Multiple sequence alignment demon-
strates that amino acid sequences derived from rabbit,
mouse, and human SPN are 
 
$
 
75% identical (Fig. 1 a). Hu-
man and rabbit SPN contain a short insertion at the NH
 
2
 
terminus, which is absent in mouse SPN. The four pre-
dicted transmembrane domains are extremely well con-
served. SPN’s membrane topology is strikingly different
from other dystrophin-associated proteins, which only
have a single pass transmembrane domain, and is reminis-
cent of the tetraspan superfamily of proteins (Wright and
Tomlinson, 1994; Maecker et al., 1997). Using phyloge-
netic analysis, we previously demonstrated that SPN is
closely related to the divergent family members Rom-1,
peripherin, and uroplakin (Crosbie et al., 1997). The tet-
raspans are thought to play important roles in mediating
interactions between transmembrane proteins as mecha-
nisms to control cell growth and adhesion. We speculate
that SPN, a novel dystrophin-associated tetraspan, may be
facilitating interactions among proteins of the DGC and
perhaps mediating interactions of the DGC components
with other sarcolemma proteins. 
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SPN Is a Unique Tetraspan Predominantly Expressed
in Muscle
 
To examine the distribution of SPN in mouse tissue, we
performed RNA hybridization analysis. Hybridization of
mouse multiple tissue Northern blots with probes repre-
senting either the coding region or the 3
 
9
 
 untranslated re-
gion of SPN gave identical results (Fig. 1 b). As shown in
Fig. 1, a 4.4-kb transcript is predominant in skeletal and
cardiac tissues, with minor transcript levels present in
lung, brain, and testis. Human skeletal and cardiac muscles
express two SPN transcripts (4.4 and 6.5 kb; Crosbie et al.,
1997). The additional 6.5-kb transcript in humans is likely
the result of alternate splicing, since the 6.5-kb transcript
does not hybridize to SPN exons 2 and 3 (Heighway et al.,
1996).
 
SPN Localization to the Sarcolemma Is Dependent
on the DGC
 
We have previously shown that SPN is expressed through-
out the sarcolemma of normal human skeletal muscle
(Crosbie et al., 1997, 1998). The limitations of patient bi-
opsies with known mutations prompted our use of murine
models as a method to investigate the interactions of SPN
with the DGC. First, we examined expression of SPN in
quadriceps femoris (thigh), diaphragm, and cardiac mus-
cles from 
 
mdx
 
 mice, a model for Duchenne muscular dys-
trophy. The 
 
mdx
 
 phenotype is inherited as an X-linked re-
cessive trait, which stems from a premature stop codon in
exon 23 of the dystrophin gene, leading to absence of dys-
trophin protein (Bulfield et al., 1984; Hoffman et al., 1987;
Chamberlain et al., 1988). As a consequence, the dystro-
phin-associated proteins are nearly ablated from the sar-
colemma (Ohlendieck and Campbell, 1991). Using indi-
rect immunofluorescence on muscle cross sections, we
show that SPN is dramatically reduced in skeletal muscle
of 
 
mdx
 
 mice (Fig. 2). Our data also demonstrate that SPN
is expressed in normal cardiac tissue, which is consistent
with the presence of SPN transcript in Northern blots (Fig.
1 b). As shown in Fig. 2, SPN is significantly reduced in
 
mdx
 
 cardiac tissue. The diaphragm muscle, which is the
most severely affected muscle in 
 
mdx
 
 mice, also lacks nor-
mal sarcolemma expression of SPN. In addition to its ex-
pression in skeletal muscle, recent experiments from our
group demonstrate that SPN is also present in smooth
muscle (Straub, V., and K.P. Campbell, personal commu-
nication). Lastly, we observed positive SPN staining in
muscle from the laminin 
 
a
 
2 deficient 
 
dy
 
 (Arahata et al.,
1993; Sunada et al., 1994; Xu et al., 1994a) and 
 
dy
 
2J
 
 (Xu et
al., 1994b; Sunada et al., 1995) mice (data not shown),
which are naturally occurring animal models of congenital
muscular dystrophy.
 
Association of SPN with Dystrophin Isoforms
 
To further explore the association of SPN with the DGC,
we examined SPN expression in a collection of dystrophin
transgenic mice. The transgenes, which were individually
expressed on an 
 
mdx
 
 background, encode truncated dys-
trophin products. Muscle from the transgenic mice was
previously evaluated for its morphology and for the ability
of the transgene to restore sarcolemma localization of the
DGC (Cox et al., 1994; Greenberg et al., 1994; Rafael et al.,
1994, 1996; Phelps et al., 1995). We detected SPN expres-
sion in skeletal muscle cross sections by indirect immuno-
fluorescence staining with SPN antibodies, and found nor-
mal levels of SPN expression in muscle from 
 
D
 
17–48
(Phelps et al., 1995), 
 
D
 
1–62 (Cox et al., 1994; Greenberg et al.,
1994),  D71–74 (Rafael et al., 1994, 1996), and D75–78
(Rafael et al., 1996) transgenic mice (Fig. 3). Despite large
deletions, these transgenes are able to restore SPN to the
sarcolemma and, with the exception of the D1–62 trans-
gene, alleviate muscular dystrophy. The D71–74 transgene
represents an alternately spliced dystrophin isoform that is
predominantly expressed in brain, and the D1–62 (Dp71)
transgene mimics a form of dystrophin present in lung,
spleen, testis, and retina.
Figure 1. SPN is a novel tetraspan expressed predominantly in
muscle. (a) Multiple amino acid sequence alignment of SPN iso-
lated from rabbit, human, and mouse skeletal muscle. Residues
identical in two or more species are shaded with gray boxes. Pre-
dicted transmembrane domains are indicated with underlining.
These sequence data are available from GenBank/EMBL/DDBJ
under accession numbers AF016028 for human, U02487 for
mouse, and AF120276 for rabbit. Mouse SPN cDNAs isolated
from Y1 adrenal carcinoma cells (Scott et al., 1994) and skeletal
muscle (this study) are identical. (b) Northern blots containing
2 mg of poly (A)1 RNA from the indicated mouse tissues were
hybridized with probes representing the 39 untranslated region
(UTR) and the coding region of mouse SPN. Molecular size
markers are indicated on the left (kb).Crosbie et al. Sarcospan: Association with the Sarcoglycan Subcomplex 157
SPN Enrichment at the NMJ Is Mediated by 
Dystrophin and Utrophin
To determine if SPN is associated with the utrophin–gly-
coprotein complex, and if replacement of dystrophin with
utrophin would affect SPN’s localization to the sarco-
lemma, we examined NMJs from dystrophin, utrophin
(Grady et al., 1997a), and dystrophin–utrophin (Deco-
ninck et al., 1997; Grady et al., 1997b) deficient muscle. The
NMJs were identified by staining cross sections of quadri-
ceps femoris with fluorescein a-bungarotoxin, which selec-
tively binds to acetylcholine receptors. By indirect immu-
nofluorescence, we show that SPN is enriched at the NMJ
of innervated muscle (Fig. 4). This enrichment is main-
tained even after denervation, demonstrating that SPN is
associated with the postsynaptic membrane (data not
shown). At the NMJ, dystrophin is replaced by the struc-
turally and functionally similar protein, utrophin (Khurana
et al., 1991; Nguyen et al., 1991; Ohlendieck et al., 1991;
Pons et al., 1991; Matsumura et al., 1992; Karpati et al.,
1993). Enrichment of SPN at the NMJ is not altered by the
absence of dystrophin, as seen by positive NMJ staining in
the mdx muscle (Fig. 4). In this case, SPN’s localization to
the NMJ is mediated by utrophin. Conversely, NMJ local-
ization of SPN is preserved by dystrophin in utrn2/2 mus-
cle, as demonstrated by SPN NMJ staining in these mice.
Loss of SPN staining from the NMJ occurs only in the ab-
sence of both utrophin and dystrophin, as in the mdx:
utrn2/2 double mutant mice.
In mdx mice, muscles with the greatest upregulation of
utrophin exhibit the least pathological changes (Porter et al.,
1998). For instance, the EOM are spared the pathological
effects in mdx mice and Duchenne muscular dystrophy pa-
tients, likely from the upregulation of utrophin (Mat-
sumura et al., 1992; Porter et al., 1998). In support of this,
Tinsley et al. (1996, 1998) demonstrate that expression of
utrophin attenuates the dystrophic pathology in mdx mice,
suggesting that utrophin can functionally replace dystro-
phin within the complex. We examined the EOMs from
wt, mdx, and mdx:utrn2/2 (Deconinck et al., 1997; Grady
et al., 1997b) mice for SPN expression as another method
to demonstrate that SPN is part of the utrophin–glycopro-
tein complex. We show that SPN is located at the sarco-
lemma of wt EOM and is maintained in the EOM of mdx
mice, despite absence of dystrophin (Fig. 5). The contin-
ued expression of SPN in the mdx EOM likely is mediated
through SPN’s association with the utrophin–glycoprotein
complex. Consistent with this idea, SPN expression is lost
in the EOM of mice lacking both dystrophin and utrophin
(mdx:utrn2/2; Fig. 5). These data are important as they
demonstrate that upregulation of utrophin retains SPN to
the sarcolemma and validates this as a reasonable therapy
for Duchenne muscular dystrophy.
SPN’s Localization to the Sarcolemma Is Dependent
on the SGs
The SGs (consisting of a, b, g, and d subunits) form a tight
subcomplex of four transmembrane glycoproteins within
the DGC (Ervasti et al., 1991; Yoshida et al., 1994; Jung
et al., 1996). The integrity of this complex is maintained
despite harsh treatments with SDS (Jung et al., 1996) and
n-octyl b-D-glucoside (Yoshida et al., 1994). Absence of
any one of the SGs results in absence of the entire SG sub-
complex and destabilization of a-DG from the sarcolemma
(Roberds et al., 1993; Duclos et al., 1998a; Holt et al.,
1998). Furthermore, this subcomplex is critical for protect-
ing the sarcolemma from contraction induced damage.
We wanted to determine if SPN depends on the SG sub-
complex for proper membrane targeting by examining
Figure 2. SPN is absent in dys-
trophin-deficient muscle. Quad-
riceps, diaphragm, and cardiac
muscle cryosections from wt and
mdx mice were stained with an-
tibodies to SPN by indirect im-
munofluorescence. SPN stain-
ing is dramatically reduced in
the dystrophin-deficient mdx
muscles. Bars, 100 mm.The Journal of Cell Biology, Volume 145, 1999 158
d-SG-deficient BIO 14.6 hamsters (Homburger et al., 1962;
Okazaki et al., 1996) for SPN expression. A large deletion
in the d-SG gene (Nigro et al., 1997; Sakamoto et al., 1997)
causes selective loss of the entire SG subcomplex from
BIO 14.6 skeletal muscle without affecting b-DG (Roberds
et al., 1993; Mizuno et al., 1995; Duclos et al., 1998b). We
now demonstrate that SPN expression is absent from the
sarcolemma (Fig. 6), as well as the NMJ (data not shown)
of the BIO 14.6 hamster. Furthermore, we show that SPN
expression is restored to normal levels after delivery of an
adenovirus encoding d-SG into BIO 14.6 muscle (Fig. 6).
Control injections of a-SG did not restore proper localiza-
tion of SPN or the SGs (Fig. 6). Recent experiments from
our laboratory have shown that injection of d-SG into
muscle of the BIO 14.6 hamster rescues expression of the
entire SG subcomplex (Holt et al., 1998). Muscle fibers ex-
pressing the restored SG–SPN subcomplex are spared the
pathological features of muscular dystrophy (i.e., sarco-
lemma damage and central nucleation) and have stable ex-
pression of a-DG at the plasma membrane (Holt et al.,
1998). Thus, SPN and the SGs are required for normal
muscle physiology and prevention of dystrophic features.
In addition to this naturally occurring hamster model for
LGMD, our laboratory has created a-SG null mice by a
targeted disruption of the murine a-SG gene (Duclos et al.,
1998b). Like the BIO 14.6 hamsters, Sgca-null mice specif-
ically lack the SG subcomplex (Duclos et al., 1998b). We
now demonstrate that Sgca-null muscle is completely de-
void of SPN (Fig. 7 a). The NMJ and myotendinous junc-
tion (MTJ), which we show are normally enriched for SPN
expression, also lack SPN in the Sgca-null mice (Fig. 7 a).
As further demonstration of the tight association of SPN
with the SGs, we immunoblotted KCl washed membranes
prepared from skeletal muscle of wt, mdx, and Sgca-null
mice. SPN is dramatically reduced in mdx membranes
(z90% compared with wt), but SPN was not detected in
the Sgca-null membranes (Fig. 7 b).
Isolation of the SG–SPN Subcomplex
To demonstrate that SPN is tightly associated with the
SGs, we isolated the SG–SPN subcomplex from skeletal
muscle. We prepared purified DGC from rabbit skeletal
muscle microsomes and titrated the complex to pH 11 to
dissociate pH-sensitive protein–protein interactions. Alka-
line-treated DGC was centrifuged through a 5–30% linear
sucrose gradient. Proteins from the sucrose gradient frac-
tions were separated by SDS-PAGE and immunoblotted
with anti-DGC antibodies. As shown in Fig. 8 a, sucrose
gradient sedimentation of alkaline-treated DGC separates
Figure 3. Restoration of SPN by
dystrophin transgenic products.
Various truncated and internally
deleted dystrophin transgenes
were expressed on an mdx back-
ground and previously analyzed
for their ability to rescue the
mdx phenotype. Skeletal mus-
cle cryosections from D17–48
(becker), D1–62 (Dp71), D71–74
(D330), and D75–78 mice were
stained with SPN antibodies and
visualized by indirect immuno-
fluorescence. The localization of
the deleted exons is represented
in the schematic diagram of the
dystrophin transgene. Binding
regions for F-actin have been
identified in the NH2 terminus,
as well as in the mid-rod domain
of dystrophin (Rybakova et al.,
1996; Rybakova and Ervasti,
1997; Amann et al., 1998). Syn-
trophin and b-DG binding sites
are located at the dystrophin
COOH terminus. Bar, 100 mm.Crosbie et al. Sarcospan: Association with the Sarcoglycan Subcomplex 159
the DG (fractions 6–9) and SG (fractions 9–12) subcom-
plexes from one another. SPN displays a sedimentation
pattern similar to that of the SG subcomplex, indicating a
preferential association of SPN with the SGs.
In addition to chemically disrupting the DGC, we
analyzed the dissociation of SG and DG subcomplexes re-
sulting from the absence of dystrophin. The dystrophin-
associated proteins are present in the extrajunctional sar-
colemma of mdx muscle, although at significantly reduced
levels. Figs. 2 and 7 illustrate that z10% of SPN expres-
sion is maintained at the mdx sarcolemma. We prepared
glycoproteins by WGA–Sepharose chromatography of
digitonin-solubilized  mdx skeletal muscle. Without dystro-
phin, the SG and DG subcomplexes are no longer associ-
ated and can be separated by sucrose gradient centrifuga-
tion. The subcomplexes peak in separate fractions and the
relative separations between the SG and DG containing
fractions are similar for both mdx and pH 11 treated sam-
ples. As shown in Fig. 8 b, SPN migrates exclusively with
the SG containing fractions.
Reconstitution of the SG–SPN Subcomplex
Using an in vivo cell expression system, we demonstrate
that SPN and the SGs are associated in a complex at the
plasma membrane. Myc-tagged human cDNA constructs
of the SGs (a, b, g, and d) and SPN were transiently intro-
duced into CHO cells by electroporation. Immunoblots of
cellular protein lysates with anti-myc antibodies demon-
strate that each of the SGs and SPN, as well as the Grb2
negative control, are expressed at relatively equal quanti-
ties (Fig. 9). We confirm that these proteins are targeted to
the plasma membrane by treatment of cells with sulfo-
NHS-biotin, which forms a covalent bond with free amines
of proteins at the cell surface. Clarified lysates from trans-
fected CHO cells were incubated with avidin–Sepharose
Figure 4. Enrichment of SPN at
the NMJ is mediated by dystro-
phin and utrophin. Sections
from quadriceps femoris mus-
cles of adult mice were doubly
stained with a-bungarotoxin
(a-BTX) and SPN antibodies.
SPN expression at the NMJ was
examined for wt, mdx, utrn2/2,
and  mdx:utrn2/2 mice. SPN
staining was visualized by indi-
rect immunofluorescence with
Cy3-conjugated secondary anti-
bodies (red) and synaptic sites
were identified by fluorescein–
a-bungarotoxin staining (green).
Merged images (yellow) are
shown in the right panels.The Journal of Cell Biology, Volume 145, 1999 160
to precipitate plasma membrane–associated proteins. As
shown in Fig. 9, SPN and the SGs are properly localized to
the plasma membrane.
To demonstrate that the SGs and SPN are assembled
into a stable molecular complex, we performed immuno-
precipitation experiments. CHO cells transfected with the
SGs plus SPN were immunoprecipitated using mAbs to
b-SG. SPN coimmunoprecipitates along with the SGs from
CHO cells. To demonstrate the specificity of this associa-
tion, control immunoprecipitation experiments from cells
expressing the SGs and myc-tagged Grb2 were performed.
Grb2 serves as a negative control since it is a soluble pro-
tein that is not expected to associate with the SGs at the
plasma membrane. The SGs and Grb2 were cotransfected
into CHO cells and cellular lysates were immunoprecipi-
tated with the b-SG mAb. Grb2 is not found in the im-
mune complex with the SGs (Fig. 9). These data provide
strong evidence that the simultaneous expression of the
SGs and SPN in CHO cells results in the formation of a
tight molecular complex.
Discussion
The DGC spans the sarcolemma and links the intracellular
actin cytoskeleton of muscle cells to the extracellular ma-
trix. Current evidence indicates that the DGC confers
structural stability to the muscle plasma membrane, thus
protecting it from stresses that develop during muscle
fiber contraction. In support of this theory, perturbations
in the dystrophin-associated components lead to loss of
membrane integrity. This is evidenced by increased per-
meability of muscle fibers to intravenously administered
Evans blue dye (Straub et al., 1997, 1998; Holt et al., 1998)
as well as leakage of muscle-specific enzymes into the se-
rum. This loss of membrane integrity eventually manifests
itself as fiber degeneration. Thus, understanding the struc-
tural organization of the DGC is critical for understanding
the function of this complex.
Our findings represent the first account of SPN’s local-
ization in normal muscle, the expression of SPN in mutant
mice, and the molecular associations of SPN within the
DGC. We report that SPN, found at the sarcolemma of
skeletal, cardiac, and diaphragm muscles, is also expressed
at many specialized muscle membrane interfaces, includ-
ing the NMJ (Fig. 4) and MTJ (Fig. 7), as well as at muscle
spindles (data not shown). SPN is also expressed in
smooth muscle, where it is part of a unique smooth muscle
SG–SPN complex (Straub, V., and K.P. Campbell, per-
sonal communication). Although SPN seems to be pre-
dominantly expressed in muscle, we detect SPN transcripts
Figure 5. SPN staining is pre-
served in the EOMs of mdx
mice by utrophin upregulation.
Cryosections from the EOMs of
wt, mdx, and mdx:utrn2/2 were
stained with antibodies to SPN,
utrophin (Utrn), and laminin a2
chain (Lam). The mdx EOM are
among the few muscles that are
spared the pathological conse-
quences of muscular dystrophy,
likely due to its sarcolemma ex-
pression of utrophin. Shown are
EOM rectus muscles. SPN ex-
pression is maintained in the
mdx EOM. Bar, 50 mm.Crosbie et al. Sarcospan: Association with the Sarcoglycan Subcomplex 161
in many nonmuscle tissues (Fig. 1 b; Crosbie et al., 1997).
Consistent with this, our examination of dystrophin trans-
genic mice indicates that SPN may be associated with non-
muscle isoforms of dystrophin, such as Dp71 (Fig. 3). Fur-
ther experimentation is necessary to determine whether
SPN protein is present in these nonmuscle tissues. The dis-
covery that a subset of dystrophin-associated proteins (i.e.,
dystrophin, DG, and e-SG) is present in a broad array of
cell types is a provocative finding since all tissues are not
subjected to the same shear stresses as muscle. This sug-
gests that the DGC may serve a more fundamental role in
the cell, in addition to the structural one ascribed to the
DGC in muscle.
We now show that SPN’s localization to the sarcolemma
is compromised in dystrophin and utrophin double null mice.
SPN’s enrichment at the NMJ is achieved by its associa-
tion with utrophin. It has been suggested that upregulation
of utrophin compensates for loss of dystrophin (Mat-
Figure 6. SPN’s absence from
the sarcolemma of d-SG-defi-
cient BIO 14.6 hamster can be
restored with recombinant d-SG
adenovirus. Quadriceps muscle
of the BIO 14.6 hamster was in-
jected with 109 particles of d-SG
adenovirus or a-SG adenovirus
particles. Tissue was harvested
7 d after injection. Muscle cryo-
sections from these injected ani-
mals, as well as from the F1B
and BIO 14.6 (uninjected) ham-
sters were examined for SPN ex-
pression by indirect immunoflu-
orescence with SPN antibodies.
Figure 7. SPN is absent from the NMJ and
MTJ of Sgca-null mice. (a) Cryosections from
Sgca-null muscle were analyzed for SPN ex-
pression at the sarcolemma, NMJ, and MTJ.
SPN is completely absent in the SG deficient
muscle. (b) Skeletal muscle membranes from
wt, mdx, and Sgca-null mice were analyzed by
3–15% SDS-PAGE and immunoblotted us-
ing antibodies against SPN. SPN isolated
from mouse skeletal muscle membranes mi-
grates at 20 kD. The level of SPN expression
is dramatically reduced in the mdx mem-
branes and is completely absent from the
Sgca-null muscle. Molecular weights are indi-
cated (3 103 D).The Journal of Cell Biology, Volume 145, 1999 162
sumura et al., 1992). Indeed, we have now demonstrated
that the EOMs of mdx mice, which are spared from the
pathological features of muscular dystrophy, express utro-
phin (Porter et al., 1998) and SPN throughout the sarco-
lemma. If utrophin can functionally replace dystrophin,
then it may be possible to upregulate utrophin expression
in Duchenne muscular dystrophy patients (Matsumura et al.,
1992; Tinsley et al., 1996, 1998). Our current data lend cre-
dence to the proposed theory that sarcolemma expression
of utrophin would completely restore the dystrophin-asso-
ciated proteins to the muscle plasma membrane.
The DGC can be broken down into at least three inter-
connected subcomplexes: dystrophin, the DGs, and the
SGs. Using several independent criteria, we demonstrate
that SPN’s localization to the sarcolemma is dependent on
an intact SG subcomplex. SPN is completely absent from
the sarcolemma, NMJ, and MTJ of the SG-deficient BIO
14.6 hamster and Sgca-null mouse. The preferential associ-
ation of SPN with the SGs is demonstrated by biochemical
isolation of the SG–SPN subcomplex. Alkaline treatment
of purified DGC causes dissociation of the complex into
distinct subcomplexes, where SPN preferentially associ-
ates with the SG containing fractions (Fig. 8 a). Likewise,
in the absence of dystrophin, the remaining extrajunc-
tional dystrophin-associated proteins dissociate into dis-
tinct protein complexes, where SPN’s specific interactions
with the SGs are maintained (Fig. 8 b).
Furthermore, we reconstitute the SG–SPN complex in a
recently developed heterologous cell system, which lacks
muscle specific proteins (Fig. 9; Holt and Campbell, 1998).
Previous work from our group has shown that mutations
in an individual SG result in intracellular accumulation of
the SG subcomplex (Holt and Campbell, 1998). These ex-
periments suggest that obligatory steps in the biosynthetic
pathway for SG subcomplex assembly cannot occur if indi-
vidual SG proteins are aberrant or missing (Holt et al.,
1998; Holt and Campbell, 1998).
Taken together, our in vivo experiments now indicate
that assembly of the SG subcomplex is a prerequisite for
targeting and stabilization of SPN to the sarcolemma, as il-
lustrated in Fig. 10. We currently do not know the molecu-
lar basis of the interaction between the SG–SPN and DG
subcomplexes. It is clear, however, that proper structural
alignment of these two subcomplexes, along with dystro-
Figure 8. Isolation of the SG–SPN subcomplex from skeletal muscle. (a) The DGC, purified from rabbit skeletal muscle membranes,
was titrated to pH 11 and centrifuged through 5–30% linear sucrose gradients. Fractions from the gradients were separated by SDS-
PAGE and separately immunoblotted with antibodies to a- and b-DG, SGs, dystrophin, and SPN. Alkaline treatment dissociates the
SG subcomplex from the DG subcomplex. SPN comigrates with the SG subcomplex. (b) Glycoproteins from skeletal muscle of dystro-
phin-deficient mdx mice were prepared and centrifuged through 5–30% linear sucrose gradients. Protein fractions were immunoblotted
with the indicated antibodies. Without dystrophin, the DG and SG subcomplexes are no longer associated, and migrate separately dur-
ing sucrose gradient centrifugation. SPN preferentially associates with the SG subcomplex. Molecular size standards are indicated on
each panel (3 103 D).Crosbie et al. Sarcospan: Association with the Sarcoglycan Subcomplex 163
phin, is required for DGC function and prevention of mus-
cular dystrophy. The data presented in the current study
are also consistent with our finding that SG-deficient
LGMD patients also lack SPN (Crosbie, R.H., and K.P.
Campbell, personal communication).
Although SPN is tightly associated with the SGs, SPN
bears no structural homology to the SGs. To date, there
are five known SGs, including the ubiquitously expressed
e-SG, which exhibits .40% amino acid identity to a-SG
(Ettinger et al., 1997; McNally et al., 1998). e-SG shares all
the structural features of the skeletal muscle SGs, but is
also expressed in many nonmuscle tissues. b-, g-, and d-SG
are type II transmembrane proteins, while a- and e-SG are
type I membrane proteins with an NH2-terminal signal
sequence. e-SG expression is not perturbed by targeted
deletion of the a-SG gene, suggesting that e-SG is not an
additional member of the a-, b-, g-, d-tetrameric SG sub-
complex in skeletal muscle (Duclos et al., 1998b). Each of
the SGs have a five cysteine residue motif in its extracellu-
lar domain, which is unique to this group of proteins. The
SGs also possess one or more consensus sites for glycosy-
lation and treatment with PNGase F has been shown to
shift the molecular weight of these proteins. SPN, on the
other hand, has many characteristics that distinguish it
from the SGs. Most obviously, SPN is predicted to have
multiple transmembrane domains and has no consensus
sites for N-linked glycosylation. Consistent with this, treat-
ment of purified DGC with PNGase F does not alter
SPN’s molecular weight (data not shown). Thus, SPN rep-
resents the first non-SG protein to be associated with the
SG subcomplex of the DGC.
Figure 9. Reconstitution of the SG–SPN subcomplex. The SG–
SPN subcomplex was reconstituted in vivo using a heterologous
cell expression system. CHO cells were transfected with expres-
sion vectors encoding myc-tagged human a-, b-, g-, and d-SGs
with either SPN (SGs 1 SPN) or Grb2 (SGs 1 Grb2). Mock
transfected CHO cells are shown. To demonstrate similar expres-
sion of proteins, whole cell lysates are shown (lysates). Note that
Grb2, which serves as a negative control, and SPN migrate at
similar molecular weights. Cells transfected with all four SGs and
SPN were treated with NHS-biotin and recovered from detergent
extracts as avidin precipitates to demonstrate surface localization
of these proteins (NHS). Immunoprecipitation of b-SG from ly-
sates prepared from cells expressing all four SGs and SPN results
in coprecipitation of the SG–SPN subcomplex (b-SG IP). Grb2
does not immunoprecipitate with the SGs. Proteins are detected
by immunoblotting with an anti-myc mAb, which recognizes
the 9E10 tag on each protein construct. The 50-kD protein band
in the mock transfected cell represents the b-SG immunoprecipi-
tating antibody. Molecular weights are indicated on each blot (3
103 D).
Figure 10. Schematic dia-
gram representing interac-
tions among DGC subcom-
plexes. Evidence presented
in the current report demon-
strates that assembly and
membrane localization of the
SG subcomplex are prerequi-
sites for SPN localization to
the sarcolemma, NMJ, and
MTJ. This dependence is
likely mediated through di-
rect interaction of SPN with
the SGs, as suggested by co-
fractionation and coimmuno-
precipitation of SPN with the
SG subcomplex. In the ab-
sence of the SG–SPN sub-
complex, a-DG is not prop-
erly anchored to the muscle
plasma membrane. This sug-
gests that there may be direct
interactions between a-DG
and the SG–SPN subcom-
plex, which stabilize a-DG to
the cell membrane (dashed
arrows). The molecular basis
of the interaction between
the SG–SPN and DG subcomplexes is not thoroughly understood. Clearly, proper structural alignment of the two subcomplexes along
with dystrophin is required for DGC function and prevention of muscular dystrophy.The Journal of Cell Biology, Volume 145, 1999 164
The tight association of SPN with the SGs is consistent
with SPN’s homology to the tetraspan superfamily of pro-
teins. The tetraspans are thought to function as facilitators
of transmembrane protein interactions, and we suspect
SPN serves to coordinate protein–protein interactions
within the DGC. The results of our study provide support
for this notion, since we find that SPN is intimately associ-
ated with at least one subcomplex of the DGC. Further ex-
amination of SPN’s interaction with other DGC subcom-
plexes should provide significant insight into how the
DGC is structurally organized, which is critical for under-
standing the function of this complex.
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